Eli Lilly (LLY) has partnered with Chinese healthcare platform JD Health International to sell its drugs for obesity and diabetes online, Amber Tong of Bloomberg reports, citing a statement from the company on its WeChat account. The partnership will allow Lilly’s drugs for obesity, diabetes, and alopecia to be sold on JD Health’s platform, which provides consultations, prescriptions, drug delivery, and follow-up services.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly Temporarily Stops U.K. Shipments of Its Weight-Loss Drug
- Cautious Outlook on Eli Lilly’s Orforglipron Amid Promising Results and Competitive Challenges
- Eli Lilly’s Orforglipron Shines in ATTAIN-2 Trial, Securing Buy Rating with Promising Market Position
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Eli Lilly’s Stock (LLY) Is Upgraded by HSBC as Weight-Loss Pill Moves Closer to Approval